Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia

David McConkey, Joya Chandra

Research output: Contribution to journalReview article

Abstract

Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea that CLL is a disease involving defective apoptosis is particularly attractive. Recent studies have identified many of the central components of the apoptotic pathway that appear to be conserved from one cell type to another. Thus, investigation into the functionality of these molecules should reveal where the defect(s) in apoptosis may lie in CLL cells. Protease activation is a central event during apoptosis, and leads to many of the familiar characteristics of apoptosis. Here we will examine the role of apoptotic proteases in CLL and speculate on their contribution to disease emergence and drug resistance.

Original languageEnglish (US)
Pages (from-to)421-431
Number of pages11
JournalLeukemia and Lymphoma
Volume33
Issue number5-6
StatePublished - 1999
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Glucocorticoids
Peptide Hydrolases
Apoptosis
Disease Resistance
Drug Resistance
Lymphocytes
Pharmaceutical Preparations

Keywords

  • Chronic lymphocytic leukemia
  • Glucocorticoid-induced apoptosis
  • Protease activation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia. / McConkey, David; Chandra, Joya.

In: Leukemia and Lymphoma, Vol. 33, No. 5-6, 1999, p. 421-431.

Research output: Contribution to journalReview article

@article{65d479ab11d244f7be3807316b99466c,
title = "Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia",
abstract = "Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea that CLL is a disease involving defective apoptosis is particularly attractive. Recent studies have identified many of the central components of the apoptotic pathway that appear to be conserved from one cell type to another. Thus, investigation into the functionality of these molecules should reveal where the defect(s) in apoptosis may lie in CLL cells. Protease activation is a central event during apoptosis, and leads to many of the familiar characteristics of apoptosis. Here we will examine the role of apoptotic proteases in CLL and speculate on their contribution to disease emergence and drug resistance.",
keywords = "Chronic lymphocytic leukemia, Glucocorticoid-induced apoptosis, Protease activation",
author = "David McConkey and Joya Chandra",
year = "1999",
language = "English (US)",
volume = "33",
pages = "421--431",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Protease activation and glucocorticoid-induced apoptosis in chronic lymphocytic leukemia

AU - McConkey, David

AU - Chandra, Joya

PY - 1999

Y1 - 1999

N2 - Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea that CLL is a disease involving defective apoptosis is particularly attractive. Recent studies have identified many of the central components of the apoptotic pathway that appear to be conserved from one cell type to another. Thus, investigation into the functionality of these molecules should reveal where the defect(s) in apoptosis may lie in CLL cells. Protease activation is a central event during apoptosis, and leads to many of the familiar characteristics of apoptosis. Here we will examine the role of apoptotic proteases in CLL and speculate on their contribution to disease emergence and drug resistance.

AB - Chronic lymphocytic leukemia (CLL) is at present an incurable disease. All of the drugs used in the treatment of CLL induce apoptosis in the cells, and in vitro responses to glucocorticoid or analogs correlate with in vivo sensitivity to these agents. Since CLL lymphocytes accumulate rather than proliferate, the idea that CLL is a disease involving defective apoptosis is particularly attractive. Recent studies have identified many of the central components of the apoptotic pathway that appear to be conserved from one cell type to another. Thus, investigation into the functionality of these molecules should reveal where the defect(s) in apoptosis may lie in CLL cells. Protease activation is a central event during apoptosis, and leads to many of the familiar characteristics of apoptosis. Here we will examine the role of apoptotic proteases in CLL and speculate on their contribution to disease emergence and drug resistance.

KW - Chronic lymphocytic leukemia

KW - Glucocorticoid-induced apoptosis

KW - Protease activation

UR - http://www.scopus.com/inward/record.url?scp=0032958871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032958871&partnerID=8YFLogxK

M3 - Review article

C2 - 10342570

AN - SCOPUS:0032958871

VL - 33

SP - 421

EP - 431

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -